On August 22nd, the UK’s drug regulation agency — UK Medicines and Healthcare products Regulatory Agency — approved Eisai and Biogen’s anti-amyloid drug Leqembi … Continue reading UK Health Services Says Leqembi Is Too Costly, Too Risky to Cover